PT  - JOURNAL ARTICLE
AU  - ,
AU  - Baillie, J. Kenneth
AU  - Baruch, Joaquin
AU  - Beane, Abigail
AU  - Blumberg, Lucille
AU  - Bozza, Fernando Augusto
AU  - Broadley, Tessa
AU  - Burrell, Aidan
AU  - Carson, Gail
AU  - Citarella, Barbara Wanjiru
AU  - Dunning, Jake
AU  - Elotmani, Loubna
AU  - Garcia Barrio, Noelia
AU  - Goffard, Jean-Christophe
AU  - Hall, Matthew
AU  - Hashmi, Madiha
AU  - Horby, Peter
AU  - Jassat, Waasila
AU  - Kartsonaki, Christiana
AU  - Kumar Tirupakuzhi Vijayaraghavan, Bharath
AU  - Kumar Vecham, Pavan
AU  - Laouenan, Cedric
AU  - Lissauer, Samantha
AU  - Martin-Loeches, Ignacio
AU  - Mentre, France
AU  - Morton, Ben
AU  - Munblit, Daniel
AU  - Nekliudov, Nikita A.
AU  - Nichol, Alistair
AU  - Ong, David S.Y.
AU  - Panda, Prasan Kumar
AU  - Jimenez, Miguel Pedrera
AU  - Petrovic, Michelle
AU  - Ramakrishnan, Nagarajan
AU  - Ramos, Grazielle Viana
AU  - Roger, Claire
AU  - Rojek, Amanda
AU  - Sandulescu, Oana
AU  - Semple, Malcolm G.
AU  - Sharma, Pratima
AU  - Shrapnel, Sally
AU  - Sigfrid, Louise
AU  - Sim Lim Heng, Benedict
AU  - Singh, Budha Charan
AU  - Somers, Emily
AU  - Streinu-Cercel, Anca
AU  - Taccone, Fabio S.
AU  - Wei, Jia
AU  - Wils, Evert-Jan
AU  - Wong, Xin Ci
AU  - Young, Kyle
AU  - Olliaro, Piero L.
AU  - Merson, Laura
TI  - ISARIC COVID-19 Clinical Data Report: Final report January 2020 – January 2023
AID  - 10.1101/2020.07.17.20155218
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2020.07.17.20155218
4099  - http://medrxiv.org/content/early/2023/09/27/2020.07.17.20155218.short
4100  - http://medrxiv.org/content/early/2023/09/27/2020.07.17.20155218.full
AB  - ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global participation has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report, our 18th and final report, is a part of a series published over 3 years. Data have been entered for 945,317 individuals from 1807 partner institutions and networks across 76 countries.The comprehensive analyses detailed in this report includes hospitalised individuals of all ages for whom data collection occurred between 30 January 2020 and up to and including 10 January 2023, AND who have laboratory-confirmed SARS-COV-2 infection or clinically diagnosed COVID-19.For the 845,291 cases who meet eligibility criteria for this report, selected findings include:Median age of 57 years, with an approximately equal (50/50) male:female sex distribution29% of the cohort are at least 70 years of age, whereas 6% are 0-19 years of ageThe most common symptom combination in this hospitalised cohort is shortness of breath, cough, and history of fever, which has remained constant over timeThe five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion, which is unchanged from the previous reportsAge-associated differences in symptoms are evident, including the frequency of altered consciousness increasing with age, and fever, respiratory and constitutional symptoms being present mostly in those 40 years and above15% of patients with relevant data available (845,291) were admitted at some point during their illness into an intensive care unit (ICU), which has decreased from 19% during the 3 years of ISARIC reportingAntibiotic agents were used in 37% of patients for whom relevant data are available (802,241), a significant reduction from our previous reports (80%) which reflects a shifting proportion of data contributed by different institutions; in ICU/HDU admitted patients with data available (64,669), 90% received antibioticsUse of corticosteroids was reported in 25% of all patients for whom data were available (809,043); in ICU/HDU admitted patients with data available (64,713), 71% received corticosteroidsOutcomes are known for 762,728 patients and the overall estimated case fatality ratio (CFR) is 22% (95%CI 21.9-22), rising to 36% (95%CI 35.6-36.1) for patients who were admitted to ICU/HDU, demonstrating worse outcomes in those with the most severe diseaseTo access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric.net/ccp/ https://isaric4c.net/ Funding StatementThis work was made possible by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z, 222410/Z/21/Z, 225288/Z/22/Z and 220757/Z/20/Z]; the Bill & Melinda Gates Foundation [OPP1209135]; the philanthropic support of the donors to the University of Oxford COVID-19 Research Response Fund (0009109); grants from the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC PC 19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), (award 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award ISBRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support; CIHR Coronavirus Rapid Research Funding Opportunity OV2170359 and the coordination in Canada by Sunnybrook Research Institute; funding by the Health Research Board of Ireland [CTN-2014-12]; the Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; Cambridge NIHR Biomedical Research Centre (award NIHR203312); a Research Council of Norway grant no 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; the Comprehensive Local Research Networks (CLRNs) of which PJMO is an NIHR Senior Investigator (NIHR201385); Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115523 COMBACTE, resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007- 2013) and EFPIA companies, in-kind contribution; Stiftungsfonds zur Forderung der Bekampfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna, Project Number: APCOV22BGM; funding from Medical University of Vienna, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine; Italian Ministry of Health Fondi Ricerca corrente L1P6 to IRCCS Ospedale Sacro Cuore Don Calabria; Australian Department of Health grant (3273191); Gender Equity Strategic Fund at University of Queensland, Artificial Intelligence for Pandemics (A14PAN) at University of Queensland, the Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS, CE170100009), the Prince Charles Hospital Foundation, Australia; Australian Department of Health grant (3273191); grants from Instituto de Salud Carlos III, Ministerio de Ciencia, Spain; Brazil, National Council for Scientific and Technological Development Scholarship number 303953/2018- 7; the Firland Foundation, Shoreline, Washington, USA; the French COVID cohort (NCT04262921) is sponsored by INSERM and is funded by the REACTing (REsearch and ACtion emergING infectious diseases) consortium and by a grant of the French Ministry of Health (PHRC 20-0424); a grant from foundation Bevordering Onderzoek Franciscus; a grant from foundation Bevordering Onderzoek Franciscus; the South Eastern Norway Health Authority and the Research Council of Norway; Institute for Clinical Research (ICR), National Institutes of Health (NIH) supported by the Ministry of Health Malaysia; the U.S. DoD Armed Forces Health Surveillance Division, Global Emerging Infectious Diseases Branch to the U.S Naval Medical Research Unit No. TWO (NAMRU-2) (Work Unit #: P0153 21 N2). These authors would like to thank Vysnova Partners, Inc. for the management of this research project. The Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit is funded by the Wellcome Trust; Branco Weiss Fellowship, Google.org, the Oxford Martin School, the Rockefeller Foundation, and the European Union Horizon 2020 project MOOD (#874850). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval for this work was given by the World Health Organisation Ethics Review Committee (RPC571 and RPC572 on 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central Oxford C Research Ethics Committee in England (Ref 13/SC/0149) and the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the United Kingdom and the Human Research Ethics Committee (Medical) at the University of the Witwatersrand in South Africa as part of a national surveillance programme (M160667) collectively representing the majority of the data. Other institutional and national approvals are in place as per local requirements.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome applications for access to data on the COVID-19 Data Sharing Platform via the Data Access Committee (www.iddo.org/covid-19). https://www.iddo.org/covid-19